• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

C4 Therapeutics, Inc. - Common Stock (NQ:CCCC)

2.765 -0.015 (-0.54%)
Delayed Quote Updated: 4:00 PM EDT, Oct 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,359,351
Open 2.780
Bid (Size) 2.720 (400)
Ask (Size) 2.860 (100)
Prev. Close 2.780
Today's Range 2.695 - 2.810
52wk Range 1.690 - 5.170
Shares Outstanding 48,797,226
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Gapping stocks in Friday's session ↗
October 09, 2026
Via Chartmill
News headline image
C4 Therapeutics Presents New Biomarker Data from the Cemsidomide Phase 1 Trial with Dexamethasone and Phase 1b Trial with Elranatamab (ELREXFIO®) in Relapsed/Refractory Multiple Myeloma at the 23rd International Myeloma Society (IMS) Annual Meeting
September 25, 2026
From C4 Therapeutics, Inc.
Via GlobeNewswire

Performance

52-Week Range 46.5% below 52-week high
2.765
1.6952W Low 5.1752W High
1 Week 16.2% below 1-week high
2.591W Low 3.301W High

C4 Therapeutics, Inc. - Common Stock (CCCC) traded between $1.69 and $5.17 over the past 52 weeks and last traded at $2.77, 46.5% below its 52-week high. Over the past week it ranged between $2.59 and $3.30.

Past 12 Months
-9.6%
-19.9%
-25.1%
-5.3%
+43.3%
+11.5%
1W -$0.29
1M -$0.69
3M -$0.92
6M -$0.15
YTD +$0.84
1Y +$0.29

CCCC was +11.5% over the past year, -5.3% over six months, +43.3% year to date, -9.6% in the last week.

12 Months vs Market
CCCC
+11.5%
DIA
+13.0%
SPY
+15.5%
QQQ
+18.3%
IWM
+10.4%

Over the past 12 months CCCC returned +11.5% versus DIA (Dow) +13.0%, SPY (S&P 500) +15.5%, QQQ (Nasdaq 100) +18.3% and IWM (Russell 2000) +10.4%.

Volume & Liquidity 1.00× 3-mo avg
Today 2,359,351 3-mo avg 2.4M
1W
2.8M
1M
2.4M
3M
2.4M
6M
2.7M
YTD
2.6M
1Y
2.5M

CCCC most recently traded 2,359,351 shares against a 3-month average daily volume of 2.4M.

More News

Read More
News headline image
C4 Therapeutics to Present New Biomarker Data on the Immunomodulatory Effects of Cemsidomide in Combination with Dexamethasone from its Phase 1 Relapsed/Refractory Multiple Myeloma Trial at the 23rd International Myeloma Society (IMS) Annual Meeting
September 03, 2026
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
C4 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
August 11, 2026
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
August 10, 2026
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population
June 11, 2026
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
C4 Therapeutics to Participate in Upcoming Conferences
May 20, 2026
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 18, 2026
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
May 12, 2026
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs)
April 09, 2026
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO®) for Relapsed/Refractory Multiple Myeloma
March 25, 2026
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
March 09, 2026
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
C4 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
February 26, 2026
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
C4 Therapeutics to Participate in Upcoming March Conferences
February 23, 2026
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
C4 Therapeutics Announces First Patient Dosed in Phase 2 MOMENTUM Trial of Cemsidomide, an Oral IKZF1/3 Degrader, in Combination with Dexamethasone for Relapsed/Refractory Multiple Myeloma
February 23, 2026
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
February 09, 2026
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
C4 Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
February 04, 2026
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
January 26, 2026
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
C4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader and Discovery Strategy Focused on Novel Targets in Clinically Validated Pathways
January 14, 2026
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
C4 Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference
November 25, 2025
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
C4 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
November 06, 2025
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
C4 Therapeutics Announces Pricing of $125 Million Underwritten Offering
October 16, 2025
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
October 03, 2025
Via Benzinga
News headline image
C4 Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Pfizer for the Combination of Cemsidomide and Elranatamab for the Treatment of Relapsed/Refractory Multiple Myeloma
October 01, 2025
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
September 22, 2025
Via Benzinga

Frequently Asked Questions

Is C4 Therapeutics, Inc. - Common Stock publicly traded?
Yes, C4 Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does C4 Therapeutics, Inc. - Common Stock trade on?
C4 Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for C4 Therapeutics, Inc. - Common Stock?
The ticker symbol for C4 Therapeutics, Inc. - Common Stock is CCCC on the Nasdaq Stock Market
What is the current price of C4 Therapeutics, Inc. - Common Stock?
The current price of C4 Therapeutics, Inc. - Common Stock is 2.765
When was C4 Therapeutics, Inc. - Common Stock last traded?
The last trade of C4 Therapeutics, Inc. - Common Stock was at 10/16/26 04:00 PM ET
What is the market capitalization of C4 Therapeutics, Inc. - Common Stock?
The market capitalization of C4 Therapeutics, Inc. - Common Stock is 134.92M
How many shares of C4 Therapeutics, Inc. - Common Stock are outstanding?
C4 Therapeutics, Inc. - Common Stock has 135M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap